RCT | Trial of Anti-BDCA2 antibody Litifilimab for cutaneous Lupus Erythematosus.

Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: BDCA2-Targeting Antibody May Be Effective for Cutaneous Lupus — In small randomized trial, litifilimab shows superiority over placebo for skin disease activity – MedPage Today (free registration required)

Commentary on Twitter

Litifilimab, a blood dendritic cell antigen 2 antibody, was superior to placebo with regard to a measure of disease activity in cutaneous lupus erythematosus at 16 weeks. https://t.co/1hQVnzMOYV pic.twitter.com/mPkFp23TnA

— NEJM (@NEJM) July 27, 2022